Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: An open-label multicenter study

Transplant International

Volumn 25, Issue 3, 2012, Pages 283-293

  Sańko Resmer, Joanna ^a   Boillot, Olivier ^b   Wolf, Philippe ^c   Thorburn, Douglas ^d,e  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c HÔPITAL DE HAUTEPIERRE   (France)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

hepatic transplantation; immunosuppression; phase III; prolonged release

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TINNITUS; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL MARKERS; CREATININE; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TREATMENT OUTCOME;

EID: 84856818848     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01412.x     Document Type: Article

References (20)

1. Mor E, Gonwa TA, Husberg BS, Goldstein RM, Klintmalm GB,. Late-onset acute rejection in orthotopic liver transplantation-associated risk factors and outcome. Transplantation 1992; 54: 821.
2. Berlakovich GA, Langer F, Freundorfer E, et al. General compliance after liver transplantation for alcoholic cirrhosis. Transpl Int 2000; 13: 129.
3. O'Carroll RE, McGregor LM, Swanson V, Masterton G, Hayes PC,. Adherence to medication after liver transplantation in Scotland: a pilot study. Liver Transpl 2006; 12: 1862.
4. Chisholm MA, Mulloy LL, DiPiro JT,. Comparing renal transplant patients' adherence to free cyclosporine and free tacrolimus immunosuppressant therapy. Clin Transplant 2005; 19: 77.
5. He X, Johnston A,. Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss? Transplant Proc 2004; 36: 1321.
6. Burra P, Germani G, Canova D, et al. The impact of poor adherence to medical regimen in liver transplantation (LT). Transplantation 2008; 86: 247.
7. Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005; 16: 1839.
8. Ichimaru N, Kakuta Y, Abe T, et al. Treatment adherence in renal transplant recipients: a questionnaire survey on immunosuppressants. Transplant Proc 2008; 40: 1362.
9. Hansen R, Seifeldin R, Noe L,. Medication adherence in chronic disease: issues in posttransplant immunosuppression. Transplant Proc 2007; 39: 1287.
10. Undre NA,. Use of a once daily modified release tacrolimus regimen in de novo liver transplant recipients. Am J Transplant 2005; 5: 359. Abstract.
11. Trunecka P, Boillot O, Seehofer D, et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant 2010; 10: 2313.
12. Trunecka P, Boillot O, Langrehr J, et al. Tacrolimus once-daily prolonged release versus tacrolimus twice-daily in combination with steroids: a phase III multicentre liver study. Transplantation 2008; 86: 301. Abstract 864.
13. Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37: 1211.
14. Lucey MR, Abdelmalek MF, Gagliardi R, et al. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant 2005; 5: 1111.
15. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
16. Wilkinson A, Pham PT,. Kidney dysfunction in the recipients of liver transplants. Liver Transpl 2005; 11: S47.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461.
18. Nankivell BJ, Chapman JR, Bonovas G, Gruenewald SM,. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation 2004; 77: 1457.
19. van Hooff JP, Gelens M, Boots JM, van Duijnhoven EM, Dackus J, Christiaans MH,. Preservation of renal function and cardiovascular risk factors. Transplant Proc 2006; 38: 1987.
20. Klein IH, Abrahams A, van ET, Hene RJ, Koomans HA, Ligtenberg G,. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73: 732.